These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Assessing new therapies and their overall impact in myelofibrosis. Mesa RA Hematology Am Soc Hematol Educ Program; 2010; 2010():115-21. PubMed ID: 21239780 [TBL] [Abstract][Full Text] [Related]
8. Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies. Tibes R; Mesa RA J Hematol Oncol; 2014 Mar; 7():18. PubMed ID: 24598114 [TBL] [Abstract][Full Text] [Related]
9. State-of-the-Art Review on Myelofibrosis Therapies. Wang F; Qiu T; Wang H; Yang Q Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489 [TBL] [Abstract][Full Text] [Related]
10. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Mesa RA; Kantarjian H; Tefferi A; Dueck A; Levy R; Vaddi K; Erickson-Viitanen S; Thomas DA; Cortes J; Borthakur G; Pardanani AD; Estrov Z; Verstovsek S Cancer; 2011 Nov; 117(21):4869-4877. PubMed ID: 21480207 [TBL] [Abstract][Full Text] [Related]
12. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Mesa RA; Tefferi A Expert Opin Emerg Drugs; 2009 Sep; 14(3):471-9. PubMed ID: 19552608 [TBL] [Abstract][Full Text] [Related]
13. New drugs for the treatment of myelofibrosis. Mesa RA Curr Hematol Malig Rep; 2010 Jan; 5(1):15-21. PubMed ID: 20425392 [TBL] [Abstract][Full Text] [Related]
14. Myelofibrosis: challenges for preclinical models and emerging therapeutic targets. Morsia E; Gangat N Expert Opin Ther Targets; 2021 Mar; 25(3):211-222. PubMed ID: 33844952 [No Abstract] [Full Text] [Related]
15. Novel therapeutics and targets in myelofibrosis. Waksal JA; Harrison CN; Mascarenhas JO Leuk Lymphoma; 2022 May; 63(5):1020-1033. PubMed ID: 34852713 [TBL] [Abstract][Full Text] [Related]
16. Assessing disease burden in patients with classic MPNs. Geyer H; Mesa RA Best Pract Res Clin Haematol; 2014 Jun; 27(2):107-19. PubMed ID: 25189722 [TBL] [Abstract][Full Text] [Related]
17. Improving symptom burden and quality of life in patients with myelofibrosis: current strategies and future directions. Yoon J; Pettit K Expert Rev Hematol; 2021 Jul; 14(7):607-619. PubMed ID: 34148506 [TBL] [Abstract][Full Text] [Related]
18. The use of JAK inhibitors for low-risk myelofibrosis. Alimam S; McLornan D; Harrison C Expert Rev Hematol; 2015 Oct; 8(5):551-3. PubMed ID: 26343888 [TBL] [Abstract][Full Text] [Related]
19. Management of myelofibrosis. Vannucchi AM Hematology Am Soc Hematol Educ Program; 2011; 2011():222-30. PubMed ID: 22160038 [TBL] [Abstract][Full Text] [Related]
20. Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond. Harrison CN; McLornan DP Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):489-497. PubMed ID: 29222297 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]